CELL INTELLIGENCE · 肿瘤细胞治疗研究

Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated consistent clinical efficacy in treating advanced melanoma and other "hot" tumors.

However, it has shown limited success in "cold" tumors like glioblastoma.

We present the successful treatment of a rapidly progressing glioblastoma patient with TILs expanded using a defined cytokine combination of IL-2, IL-15, and IL-21. The patient received lymphodepletion with cyclophosphamide one day pre-TIL infusion, followed by a single dose of IL-2 post-transfer. Complete tumor regression was observed after two TIL infusions administered two weeks apart. The TIL products were enriched for CD8 + T-cells and demonstrated specific lysis of the autologous tumor cell line.

Transcriptomic analysis of tumor biopsies post-TIL infusion revealed increased expression of genes associated with immunological synapse formation and T-cell effector function, correlating with the patient's clinical outcome. T-cell receptor (TCR) next-generation sequencing of the infused TILs and post-treatment tumor biopsies confirmed the infiltration and expansion of TIL-derived clonotypes within the tumor microenvironment. CD8 + T-cell clonotypes exhibited robust tumor migration and expansion, while CD4 + T-cells showed limited tumor infiltration.

In conclusion, TILs expanded with IL-2/IL-15/IL-21 represent a promising therapeutic approach for glioblastoma, overcoming traditional challenges posed by the tumor microenvironment and achieving significant clinical outcomes. IL-2/IL-15/IL-21-expanded TILs achieved complete tumor regression in a high-TMB glioblastoma patient, overcoming the immunosuppressive microenvironment. This case highlights a novel approach for treating gliomas using tailored adoptive cell therapy strategies.